About

ReCor Medical focuses on treating hypertension, a condition that affects over 1 billion people globally. The company has created the Paradise System, which utilizes non-focused ultrasound technology to perform renal denervation, a procedure that targets kidney nerves to help lower blood pressure. This system is particularly beneficial for patients who do not respond well to standard blood pressure medications. ReCor Medical is dedicated to clinical research and development to ensure the safety and effectiveness of its technology, and it generates revenue through the sale of its medical devices and partnerships with healthcare providers. The company is also involved in significant clinical trials, such as the RADIANCE Global Program, aimed at demonstrating the benefits of renal denervation for hypertension treatment. ReCor Medical's goal is to provide a new treatment option for high blood pressure, addressing a major global health issue.

Simplify's Take

What believers are saying

• Global renal denervation market projected to grow at 35% CAGR until 2030.
• Recent FDA approval facilitates faster market entry for ReCor's Paradise System.
• Advancements in ultrasound technology enhance Paradise System's precision and safety.

What critics are saying

• Competition from Medtronic may impact ReCor's market share and pricing.
• New CEO may shift strategies, disrupting ongoing projects.
• Regulatory setbacks could delay Paradise System's market entry and revenue.

What makes ReCor Medical unique

• ReCor Medical's Paradise System uses non-focused ultrasound for renal denervation.
• The company targets hypertension patients unresponsive to traditional medications.
• ReCor Medical leads with FDA-approved renal denervation technology for hypertension.

Help us improve and share your feedback! Did you find this helpful?

YesNo